CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Autonomic nervous system (ANS) testing using portable automated devices — Coverage Policy

Policy governing coverage and medical necessity for autonomic nervous system (ANS) testing performed with portable automated devices for Medicare Advantage and commercial products under Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyAutonomic nervous system (ANS) testing using portable automated devices — Coverage Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDo not submit claims for ANS testing performed with portable automated devices for Medicare Advantage and consider them not medically necessary for Commercial Products.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredMedicare Advantage

Not medically necessaryCommercial Products

95999Suggested billing code

ListedExample devices

Coverage Criteria and Medical Necessity

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not covered / Not medically necessary

Covered when ALL of the following are met:

Main coverage determination: Autonomic nervous system testing using portable automated devices is not covered for Medicare Advantage plans and is considered not medically necessary for Commercial Products for all indications due to insufficient evidence of improvement in net health outcome.

Devices include ANX 3.0 and similar portable automated machines; testing should be performed in dedicated laboratories with expert interpretation when clinically indicated.

Specific non-covered indications for Medicare Advantage

Screening indications: Screening patients without signs or symptoms of autonomic dysfunction (including patients with diabetes, hepatic or renal disease)
Monitoring indication: Testing performed solely to monitor disease intensity or to assess treatment efficacy in diabetes, hepatic disease, or renal disease
Provider qualification: Testing performed by physicians who do not have documented training and expertise to perform and interpret ANS tests (training should be from accredited residency/fellowship or extensive continuing medical education as described)
Courses acquired via continuing medical education must be comprehensive and AMA category I or AOA equivalent where applicable.
Non-actionable results: Testing results that are not used to inform clinical decision-making or patient management
Specific device investigational status: Use of ANSAR ANX 3.0 or similar machines for screening is considered investigational and will not be covered

Evidence limitations: For individuals with signs or symptoms of ANS dysfunction, available evidence on diagnostic accuracy is limited and lacks a criterion standard for autonomic dysfunction, limiting determination of net health outcome benefit.

This evidence limitation contributes to the noncoverage / not medically necessary determination.

Screening asymptomatic patients with no signs or symptoms of autonomic dysfunction — including those with diabetes, hepatic disease, or renal disease — is not medically reasonable and necessary and will not be covered under Medicare Advantage Products. This exclusion applies to tests performed solely for screening purposes in these populations.

Autonomic nervous system testing performed solely to monitor disease intensity or to assess treatment efficacy in conditions such as diabetes, hepatic disease, or renal disease is not covered under Medicare Advantage Products. Tests ordered only for serial monitoring without impact on clinical decision-making fall under this noncoverage.

Testing performed by physicians who do not have documented training and expertise to perform and interpret autonomic nervous system tests is not covered. Required qualifications include knowledge and training obtained through an accredited residency and/or fellowship or extensive continuing medical education (AMA Category I or equivalent) that demonstrates competence to perform, interpret, and supervise ANS testing.

For Commercial Products, autonomic nervous system testing using portable, automated devices is considered not medically necessary for all indications. For Medicare Advantage, such testing is classified as not covered. These determinations reflect insufficient evidence that results from these portable automated devices improve net health outcomes.

Provider Actions, Prior Authorization, and Denials

Prior Authorization

No prior authorization is applicable for this policy.

Step Therapy

Step therapy is not applicable for this policy.

Documentation Required

Provider Qualifications and Equipment Standards

Physicians and other clinicians performing autonomic nervous system (ANS) testing must have documented training, expertise, and competency to perform and interpret ANS tests. Acceptable evidence includes completion of training within an accredited residency or fellowship program in the relevant specialty, or documented continuing medical education that is comprehensive, offered/sponsored/endorsed by a U.S. academic institution or the applicable U.S. specialty/subspecialty society and designated as AMA Category I or AOA-equivalent credit. Providers must also demonstrate the ability to assess and train personnel working under them. Equipment used for ANS testing must meet general professional standards and have appropriate regulatory clearance (e.g., FDA) as applicable. Testing should be performed in a dedicated ANS testing laboratory under closely controlled conditions, and results interpreted by individuals with expertise in ANS testing.

Training documentation: accredited residency/fellowship OR documented CME (AMA Category I/AOA)
Equipment: devices should meet professional standards and have appropriate regulatory/FDA clearance
Setting: dedicated ANS testing laboratory with controlled conditions
Personnel: providers must document competency and ability to supervise/train staff

Denial Risk

Coverage Denial for Portable Automated ANS Testing

Coverage stance: Autonomic nervous system testing using portable automated devices is considered not covered for Medicare Advantage plans and not medically necessary for Commercial products for all indications. Automated or portable ANS testing devices (examples: ANX 3.0, Sudoscan, HRV Acquire, ZYTO Hand Cradle, Finapres Nova, VitalScan) have insufficient evidence to demonstrate improvement in net health outcome and are not separately reimbursable. Non-standardized component information from ANS testing that a physician incorporates into evaluation is considered part of the physician’s basic evaluation and management service and is not separately reimbursable. Additionally, ANS testing performed by providers without documented training and expertise or testing where results are not used in clinical decision-making is not medically reasonable and necessary and will not be covered.

Not covered for Medicare Advantage: portable automated ANS testing for all indications
Not medically necessary for Commercial products: portable automated ANS testing for all indications
Examples of devices considered automated/portable: ANX 3.0, Sudoscan, HRV Acquire, ZYTO Hand Cradle, Finapres Nova, VitalScan
Non-reimbursable: non-standardized ANS component information included in physician E/M service
Denial conditions: testing by providers without documented training/expertise; testing results not used in clinical decision-making

Definitions — Test Types and Devices

inv-12: Autonomic nervous system (ANS) testing using portable automated devices — examples and device list

DefinitionTesting performed with portable, automated devices where results are generated or interpreted by computer software rather than traditional laboratory-based testing and expert human interpretation.

Examples of devicesANX 3.0; Sudoscan; HRV Acquire; ZYTO Hand Cradle; Finapres Nova Noninvasive Hemodynamic Monitor; VitalScan.

Setting recommendationANS testing is optimally performed in a dedicated ANS testing laboratory under closely controlled conditions with expert interpretation.

Rationale for concernAutomated devices with software-interpreted results have not been validated and may lead to erroneous results; evidence is insufficient to show improvement in net health outcome.

OpenPayer

Autonomic nervous system (ANS) testing using portable automated devices — Coverage Policy

Coverage Criteria and Medical Necessity

Coding and Billing Guidance

Provider Actions, Prior Authorization, and Denials

Background

Definitions — Test Types and Devices